{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:58:58Z","timestamp":1779296338799,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chapter Diagnostics","award":["2021"],"award-info":[{"award-number":["2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sexually transmitted infections (STIs) are prevalent throughout the world and impose a significant burden on individual health and public health systems. Missed diagnosis and late treatment of STIs can lead to serious complications such as infertility and cervical cancer. Although sexually transmitted co-infections are common, most commercial assays target one or a few STIs. The HPV-STI ChapterDx Next Generation Sequencing (NGS) assay detects and quantifies 29 HPVs and 14 other STIs in a single-tube and single-step PCR reaction and can be applied to tens to thousands of samples in a single sequencing run.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 274 samples, previously analyzed by conventional cytology\/histology and Roche cobas HPV Test, were analyzed by ChapterDx HPV-STI NGS assay for detection of 43 HPV and STI. A set of 43 synthetic control DNA fragments for 43 HPV and STI were developed to evaluate the limit of detection, specificity, and sensitivity of ChapterDx HPV-STI NGS assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The assay was evaluated in this study, and the limit of detection was 100% at 50 copies for all targets, and 100%, 96%, 88% at 20 copies for 34, 8, and 1 target, respectively. The performance of this assay has been compared to Roche cobas HPV test, showing an overall agreement of 97.5% for hr-HPV, and 98.5% for both, HPV16 and HPV18. The assay also detected all HPV-infected CIN2\/3 with 100% agreement with Roche cobas HPV results. Moreover, several co-infections with non-HPV STIs, such as\n                      <jats:italic>C. trachomatis<\/jats:italic>\n                      ,\n                      <jats:italic>T. vaginalis<\/jats:italic>\n                      ,\n                      <jats:italic>M. genitalium<\/jats:italic>\n                      , and HSV2 were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ChapterDx HPV-STI NGS assay is a user-friendly, easy to automate and cost-efficient assay, which provides accurate and comprehensive results for a wide spectrum of HPVs and STIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13027-022-00420-8","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T06:02:33Z","timestamp":1647842553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A comprehensive HPV-STI NGS assay for detection of 29 HPV types and 14 non-HPV sexually transmitted infections"],"prefix":"10.1186","volume":"17","author":[{"given":"Zhihai","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-6585","authenticated-orcid":false,"given":"Baback","family":"Gharizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingsheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Fellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Alejandro","family":"Basiletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita Mariel","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Celeste","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Vacchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Galarza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Alejandra","family":"Picconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"420_CR1","unstructured":"(WHO) WHO: Global health sector strategy on sexually transmitted infections, 2016\u20132021. 2018."},{"issue":"9","key":"420_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/infdis\/jiz442","volume":"222","author":"RW Eisinger","year":"2020","unstructured":"Eisinger RW, Erbelding E, Fauci AS. Refocusing research on sexually transmitted infections. J Infect Dis. 2020;222(9):1432\u20134.","journal-title":"J Infect Dis"},{"issue":"1","key":"420_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","volume":"401","author":"HU Bernard","year":"2010","unstructured":"Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70\u20139.","journal-title":"Virology"},{"key":"420_CR4","unstructured":"Humans IWGotEoCRt: Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1\u2013441."},{"issue":"6","key":"420_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Munoz","year":"2003","unstructured":"Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study G: epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"420_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ijc.2910520513","volume":"52","author":"N Munoz","year":"1992","unstructured":"Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992;52(5):743\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"420_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139.","journal-title":"J Pathol"},{"key":"420_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pvr.2016.05.004","volume":"2","author":"J Cuzick","year":"2016","unstructured":"Cuzick J, Wheeler C. Need for expanded HPV genotyping for cervical screening. Papillomavirus Res. 2016;2:112\u20135.","journal-title":"Papillomavirus Res"},{"issue":"10","key":"420_CR9","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","volume":"23","author":"EA Joura","year":"2014","unstructured":"Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997\u20132008.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"420_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ygyno.2019.02.016","volume":"153","author":"TC Wright Jr","year":"2019","unstructured":"Wright TC Jr, Parvu V, Stoler MH, Kodsi S, Eckert K, Yanson K, Cooper CK. HPV infections and cytologic abnormalities in vaccinated women 21\u201334\u00a0years of age: results from the baseline phase of the Onclarity trial. Gynecol Oncol. 2019;153(2):259\u201365.","journal-title":"Gynecol Oncol"},{"key":"420_CR11","doi-asserted-by":"crossref","unstructured":"Trevisan A, Schlecht NF, Ramanakumar AV, Villa LL, Franco EL, Ludwig-McGill Study G. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. J Gen Virol. 2013;94(Pt 8):1850\u20137.","DOI":"10.1099\/vir.0.051722-0"},{"issue":"5","key":"420_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.20480","volume":"112","author":"M Moberg","year":"2004","unstructured":"Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004;112(5):854\u20139.","journal-title":"Int J Cancer"},{"issue":"5","key":"420_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/sj.bjc.6602436","volume":"92","author":"M Moberg","year":"2005","unstructured":"Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer. 2005;92(5):891\u20134.","journal-title":"Br J Cancer"},{"issue":"4","key":"420_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1128\/JCM.37.4.1030-1034.1999","volume":"37","author":"DC Swan","year":"1999","unstructured":"Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999;37(4):1030\u20134.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"420_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1086\/647993","volume":"200","author":"LF Xi","year":"2009","unstructured":"Xi LF, Hughes JP, Edelstein ZR, Kiviat NB, Koutsky LA, Mao C, Ho J, Schiffman M. Human Papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of type-specific infection during a 2-year follow-up. J Infect Dis. 2009;200(11):1789\u201397.","journal-title":"J Infect Dis"},{"issue":"10","key":"420_CR16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/infdis\/jir049","volume":"203","author":"LF Xi","year":"2011","unstructured":"Xi LF, Hughes JP, Castle PE, Edelstein ZR, Wang C, Galloway DA, Koutsky LA, Kiviat NB, Schiffman M. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis. 2011;203(10):1425\u201333.","journal-title":"J Infect Dis"},{"issue":"6","key":"420_CR17","first-page":"1371","volume":"6","author":"AL de Abreu","year":"2016","unstructured":"de Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira EC, Pereira MW, Carvalho MD, Pelloso SM, Bonini MG, Gimenes F, et al. Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res. 2016;6(6):1371\u201383.","journal-title":"Am J Cancer Res"},{"key":"420_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2334-9-16","volume":"9","author":"R Verteramo","year":"2009","unstructured":"Verteramo R, Pierangeli A, Mancini E, Calzolari E, Bucci M, Osborn J, Nicosia R, Chiarini F, Antonelli G, Degener AM. Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect Dis. 2009;9:16.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"420_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2478\/v10039-011-0028-9","volume":"56","author":"M Biernat-Sudolska","year":"2011","unstructured":"Biernat-Sudolska M, Szostek S, Rojek-Zakrzewska D, Klimek M, Kosz-Vnenchak M. Concomitant infections with human papillomavirus and various mycoplasma and ureaplasma species in women with abnormal cervical cytology. Adv Med Sci. 2011;56(2):299\u2013303.","journal-title":"Adv Med Sci"},{"issue":"10","key":"420_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1158\/1055-9965.EPI-15-0420","volume":"24","author":"MG Discacciati","year":"2015","unstructured":"Discacciati MG, Gimenes F, Pennacchi PC, Faiao-Flores F, Zeferino LC, Derchain SM, Teixeira JC, Costa MC, Zonta M, Termini L, et al. MMP-9\/RECK Imbalance: a mechanism associated with high-grade cervical lesions and genital infection by human papillomavirus and Chlamydia trachomatis. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1539\u201347.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"420_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1469-0691.2006.01479.x","volume":"12","author":"RR Finan","year":"2006","unstructured":"Finan RR, Musharrafieh U, Almawi WY. Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin Microbiol Infect. 2006;12(9):927\u201330.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"420_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000156481","volume":"51","author":"P Paba","year":"2008","unstructured":"Paba P, Bonifacio D, Di Bonito L, Ombres D, Favalli C, Syrjanen K, Ciotti M. Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways. Intervirology. 2008;51(4):230\u20134.","journal-title":"Intervirology"},{"issue":"7","key":"420_CR23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/aje\/kwi262","volume":"162","author":"E Samoff","year":"2005","unstructured":"Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol. 2005;162(7):668\u201375.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"420_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ijc.20257","volume":"111","author":"JS Smith","year":"2004","unstructured":"Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Franceschi S, Peeling RW, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer. 2004;111(3):431\u20139.","journal-title":"Int J Cancer"},{"issue":"21","key":"420_CR25","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/jnci\/94.21.1604","volume":"94","author":"JS Smith","year":"2002","unstructured":"Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, Castellsague X, Meijer CJ, Van den Brule AJ, Franceschi S, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002;94(21):1604\u201313.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"420_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/1047-2797(94)00101-X","volume":"5","author":"ZF Zhang","year":"1995","unstructured":"Zhang ZF, Graham S, Yu SZ, Marshall J, Zielezny M, Chen YX, Sun M, Tang SL, Liao CS, Xu JL, et al. Trichomonas vaginalis and cervical cancer. A prospective study in China. Ann Epidemiol. 1995;5(4):325\u201332.","journal-title":"Ann Epidemiol"},{"issue":"10","key":"420_CR27","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1128\/JCM.00725-09","volume":"47","author":"PE Castle","year":"2009","unstructured":"Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol. 2009;47(10):3344\u20137.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"420_CR28","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1128\/JCM.05552-11","volume":"49","author":"DA Heideman","year":"2011","unstructured":"Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, Verkuijten M, Meijer CJ, Snijders PJ. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011;49(11):3983\u20135.","journal-title":"J Clin Microbiol"},{"key":"420_CR29","unstructured":"FDA: Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised), U.S. Department of Health and Human Services. Food and Drug Administration (FDA). https:\/\/www.fda.gov\/media\/135659\/download. 2020."},{"issue":"2","key":"420_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/JCM.02453-13","volume":"52","author":"C Eklund","year":"2014","unstructured":"Eklund C, Forslund O, Wallin KL, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. J Clin Microbiol. 2014;52(2):449\u201359.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"420_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1128\/JCM.40.3.779-787.2002","volume":"40","author":"AJ van den Brule","year":"2002","unstructured":"van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+\/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40(3):779\u201387.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"420_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ijc.24010","volume":"124","author":"CJ Meijer","year":"2009","unstructured":"Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516\u201320.","journal-title":"Int J Cancer"},{"issue":"4","key":"420_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ijc.10639","volume":"101","author":"KL Wallin","year":"2002","unstructured":"Wallin KL, Wiklund F, Luostarinen T, Angstrom T, Anttila T, Bergman F, Hallmans G, Ikaheimo I, Koskela P, Lehtinen M, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002;101(4):371\u20134.","journal-title":"Int J Cancer"},{"issue":"11","key":"420_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1111\/jdv.15146","volume":"32","author":"P Horner","year":"2018","unstructured":"Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? A position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32(11):1845\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"420_CR35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/AOG.0000000000003409","volume":"134","author":"F Bottari","year":"2019","unstructured":"Bottari F, Iacobone AD, Passerini R, Preti EP, Sandri MT, Cocuzza CE, Gary DS, Andrews JC. Human papillomavirus genotyping compared with a qualitative high-risk human papillomavirus test after treatment of high-grade cervical intraepithelial neoplasia: a systematic review. Obstet Gynecol. 2019;134(3):452\u201362.","journal-title":"Obstet Gynecol"},{"key":"420_CR36","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","volume":"22","author":"M Demarco","year":"2020","unstructured":"Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, Hammer A, Campos N, Kinney W, Gage JC, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"420_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/s-0032-1314959","volume":"72","author":"M Jentschke","year":"2012","unstructured":"Jentschke M, Soergel P, Hillemanns P. Importance of HPV genotyping for the screening, therapy and management of cervical neoplasias. Geburtshilfe Frauenheilkd. 2012;72(6):507\u201312.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"8","key":"420_CR38","doi-asserted-by":"publisher","first-page":"e0255914","DOI":"10.1371\/journal.pone.0255914","volume":"16","author":"M Ardhaoui","year":"2021","unstructured":"Ardhaoui M, Ennaifer E, De Matos Salim AC, Gomez FM, Laasili T, Boubaker MS, Guizani I. Nested PCR followed by NGS: Validation and application for HPV genotyping of Tunisian cervical samples. PLoS ONE. 2021;16(8):e0255914.","journal-title":"PLoS ONE"},{"issue":"12","key":"420_CR39","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41416-020-01111-0","volume":"123","author":"LS Arroyo Muhr","year":"2020","unstructured":"Arroyo Muhr LS, Lagheden C, Lei J, Eklund C, Nordqvist Kleppe S, Sparen P, Sundstrom K, Dillner J. Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. Br J Cancer. 2020;123(12):1790\u20135.","journal-title":"Br J Cancer"},{"issue":"5","key":"420_CR40","doi-asserted-by":"publisher","first-page":"e01794-18","DOI":"10.1128\/JCM.01794-18","volume":"57","author":"S Wagner","year":"2019","unstructured":"Wagner S, Roberson D, Boland J, Yeager M, Cullen M, Mirabello L, Dunn ST, Walker J, Zuna R, Schiffman M, et al. Development of the TypeSeq assay for detection of 51 human papillomavirus genotypes by next-generation sequencing. J Clin Microbiol. 2019;57(5):e01794-18.","journal-title":"J Clin Microbiol"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-022-00420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-022-00420-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-022-00420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T06:06:20Z","timestamp":1647842780000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-022-00420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1186\/s13027-022-00420-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.24.21266783","asserted-by":"object"}]},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"18 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This cohort is part of a screening study that is being carried out by the INEI-ANLIS Malbr\u00e1n with the collaboration of the \u201cProf. A. Posadas\u201d Hospital (Argentina); it was approved by the Research Ethics Board and the Ethics Committee of this hospital. Written informed consent was obtained before enrolling the participant women, and confidentiality and anonymity were guaranteed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ZM, BG, and CW are shareholders and employees of Chapter Diagnostics. A patent has been issued for the technology. The INEI-ANLIS Malbr\u00e1n investigators declare no competing interests; they did not receive any financial contribution from Chapter Diagnostics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}